Clinical trial · Interventional
Proton Therapy for Mediastinal Lymphoma (PROMLY)
NCT07817641CI-TRIAL-00126281PROMLYrecruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 15, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260915-000001
Summary
Brief summary (as posted)
The study aims to investigate whether proton therapy is feasible in a national setting and whether proton therapy can reduce the risk of late toxicity (secondary cancers and heart toxicity) compared to foton therapy.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Diffuse Large B Cell Lymphoma (DLBCL) | Diffuse Large B-Cell Lymphoma | ALIAS | 0.90 |
| Hodgkin Disease Lymphoma | — | UNRESOLVED | — |
| Mediastinal Lymphoma | Mediastinal Lymphoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Proton therapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Proton
- description
- Patients will receive proton therapy based on selection criteria
- interventionNames
- Radiation: Proton therapy
Primary outcomes (1)
- measure
- Correlation between ΔNTCP_expected and ΔNTCP_delivered.
- timeFrame
- From enrollment to end of radiotherapy, average 5 weeks.
- description
- The correlation between ΔNTCP\_expected and ΔNTCP\_delivered, is an investigation to see whether the ΔNTCP (ΔNTCP\_expected) calculated from the planning CT from the refering center, correlates with the ΔNTCP from the actual delivered plan (ΔNTCP\_delivered) at the Danish Centre for Particle Therapy.
Secondary outcomes (1)
- measure
- Incidence of acute, late toxicity and other events
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients 18 years or older * Histologically proven Hodgkin or non-Hodgkin lymphoma * Disease constrained within the mediastinum +/- neck and/or axilla involvement. * Candidates for curative intended treatment * Signed written informed consent. Exclusion Criteria: * Prior radiotherapy to the thorax * Other current malignancy * Inability to attend full course of radiotherapy or follow-up visits in the outpatient clinic.
References
Publications (0)
Data not yet available
No reference posted for this study.